logo-loader

ValiRx makes milestone payment as lead compound progresses

Last updated: 06:30 17 Mar 2015 GMT, First published: 07:30 17 Mar 2015 GMT

drug_research_350_5507d9201da36

Drug developer ValiRx (LON:VAL) has paid £80,000 to Cancer Research Technology (CRT) after lead drug VAL201 passed first patient dosing in its ongoing phase/II trial.

CRT took the milestone payment in shares at an equivalent price of 0.26p.

ValiRx announced last month that the VAL201 was safe and well tolerated at the doses tested in the trial, which is on patients suffering locally advanced or metastatic prostate cancer and other advanced solid tumours.

Satu Vainikka, chief executive, said the milestone payment was both a vindication of recent progress and, by CRT taking shares, a substantial vote of confidence in ValiRx's future prospects.


Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

2 hours, 47 minutes ago